• Our Team
  • GP Symposium 2025
  • GP Heart Blog
  • Patient Info
  • New patient form
  • Contact
Menu

Cardiology Institute

Unit 109, 119 Apollo Drive, Albany, Auckland
consult@cardiologist.co.nz
P: xxx-xxxx; F xxx-xxxx
Unit 109, 119 Apollo Drive, Albany, Auckland. P: 000-0000. F: 000-0000. consult@cardiologist.co.nz. EDI: cardinst

T 09-980-6363. M 022-672-8255. F 09-929-3248. consult@cardiologist.co.nz. EDI: CARDINST

North Shore - Suite 109, Level 1, 119 Apollo Drive, Albany

Silverdale - Northern Specialist Centre @Beyond; 5 Painton Road, Silverdale.

Central Auckland - 110 Specialist Centre @ Beyond;v110 Grafton Road, Grafton

East Auckland - East Care Specialist Centre, 260 Botany Road, Howick, Manukau

Cardiology Institute

  • Our Team
  • GP Symposium 2025
  • GP Heart Blog
  • Patient Info
  • New patient form
  • Contact

ECG - My Approach

September 7, 2019 Andrew To
Screen+Shot+2019-09-06+at+10.50.58+PM.jpg

ECG interpretation could be difficult, but a simplified approach would serve us well 95% of the time. Here is my approach:

Read more
In ECG Case Tags Bradycardia, Tachycardia, ECG

NTproBNP - when should I actually order one?

September 6, 2019 Andrew To
BNP Synthesis; JACC 2016;68:22

BNP Synthesis; JACC 2016;68:22

NTproBNP is a very useful test in heart failure. However, often it is overused, as the diagnosis of heart failure should be a clinical one.

Here are the scenarios where it may be useful:

Read more
In Heart Failure Tags BNP, heart failure

Hypertension treatment – how should we choose?

September 6, 2019 Andrew To
Billy Apple @ Auckland Art Gallery 2015 (2 Minutes 33 Seconds (Red))

Billy Apple @ Auckland Art Gallery 2015 (2 Minutes 33 Seconds (Red))

First line agents for hypertension are one of three classes:

-       ACE inhibitors or Angiotensin receptor blockers

-       Thiazides

-       Calcium channel blockers

Drug preference is mainly influenced by co-morbidities and contraindications, rather than a simple age cut-off. 

Read more
In Hypertension, Drug Treatment Tags beta blocker, ACE inhibitor, calcium channel blocker, hypertension, thiazide

Beta-blockers in Hypertension

September 5, 2019 Andrew To

70-year-old asymptomatic man with hypertension but not cardiovascular disease presented for a routine check. His pulse rate was 40bpm.  His son, aged 45, recently had an MI in Australia.

His medications include

  • Doxazosin 8mg OD

  • Metoprolol 95mg CR OD – since 2006

  • Cilazapril 5mg / Hydrochlorothiazide 12.5mg OD

ECG shows sinus bradycardia, with normal PR interval, QRS duration.

Read more
In Drug Treatment Tags hypertension, beta-blocker, calcium channel blocker, ACE inhibitor, angina, coronary artery disease, heart failure

BP therapy initiation - Combination vs. Single Agent

September 4, 2019 Andrew To
Expected BP lowering with different anti-hypertensive classes and dosages.

Expected BP lowering with different anti-hypertensive classes and dosages.

65M with Type 2 diabetes on oral hypoglycaemics but no proven coronary artery disease, BP 150/95mmHg despite 3 months of intensive lifestyle modifications, not currently on anti-hypertensives. Would you?

-      Introduce low dose ACE inhibitors, with gradual up-titration

-      Introduce combination ACE inhibitor / thiazide, with up-titration later on

Read more
In Drug Treatment, Hypertension Tags hypertension, Side effects, calcium channel blocker, ACE inhibitor, thiazide, beta blocker, primary prevention

Endocarditis prophylaxis

February 21, 2019 Andrew To
Enterococcus faecalis

Enterococcus faecalis

Antibiotic prophylaxis is suggested for patients with cardiac conditions that confer the highest risk of adverse outcome from infective endocarditis.

Read more
In Drug Treatment, Valvular heart disease Tags endocarditis, antibiotics

Making sense of an echocardiogram report - for GPs!

January 29, 2019 Andrew To

GPs often receive echocardiogram reports and are asked to interpret them. Here is a grossly simplified version of how. 

Read more
In Cardiac Investigations Tags echocardiography

Fish oil supplement? - update 2018

September 3, 2018 Andrew To
Monterey Aquarium

Monterey Aquarium

Daily supplementation with marine-derived omega-3 fatty acids has been promoted for its potential health benefits in cardiovascular diseases. We blogged about this last year with a meta-analysis from Oxford. Here is the update.

The promised randomized controlled trial has now come out after the European Society of Cardiology Congress in Munich last week.

Read more
In Coronary artery disease Tags coronary artery disease, Dietary intervention, cardiac rehabilitation

Alcohol consumption risk thresholds

August 6, 2018 Andrew To
See below!

See below!

Despite apparent “benefit” for heart attacks, increasing levels of alcohol consumption increase the risk of all-cause mortality and of cancers specifically, meaning that the level of consumption that minimises health loss is probably zero. At most, 100g per week is the absolute maximum before which risk increases significantly.

Read more
In Hypertension, Lifestyle modification, Myocardial infarction Tags alcohol, primary prevention

Duration of anti-platelets – a 2018 update

April 22, 2018 Andrew To
Cumulative Incidence of Major Adverse Cardiovascular and Cerebrovascular Events, According to Study Group. DAPT trial

Cumulative Incidence of Major Adverse Cardiovascular and Cerebrovascular Events, According to Study Group. DAPT trial

64F presented with chest pain, consistent with non-ST elevation myocardial infarction with preserved systolic function. At invasive angiogram, right coronary artery was successfully stented with a drug eluting stent. On hospital discharge, she was given Aspirin, Ticagrelor as dual anti-platelet agents. How long should the dual antiplatelet therapy be continued for?

Read more
In Drug Treatment, Myocardial infarction Tags dual antiplatelet therapy, Bleeding, clopidogrel, ticagrelor, aspirin

Nocturnal hypertension

April 20, 2018 Andrew To
Arboria, 2015 @ Aotea Square

Arboria, 2015 @ Aotea Square

65M presented for a general health check, asymptomatic on systems enquiries.  BP was 150/90mmHg with no other abnormalities. You decided to send him for an ambulatory blood pressure monitor to establish if more aggressive intervention is necessary. The report states that he is not a nocturnal dipper. His average diurnal BP was 145/85mmHg. Would medications be necessary? Is there anything else we should consider?

Read more
In Hypertension, Drug Treatment Tags hypertension, obstructive sleep apnoea, obesity
1 Comment

Lifestyle changes for hypertension – exactly how effective is it?!

April 19, 2018 Andrew To
Topolobampo, Chicago, IL

Topolobampo, Chicago, IL

In general practice (and in secondary care), we discuss at length lifestyle modifications that aid blood pressure lowering. But exactly how effective are the various strategies?

There are 5 things we could do to reduce our blood pressure, without medications.

Read more
In Hypertension, Drug Treatment Tags hypertension, Risk assessment, primary prevention

Atrial fibrillation – is there a role for lifestyle modification?

February 9, 2018 Andrew To
Chocolate, camote, coconut @ Topolobampo, Chicago, IL

Chocolate, camote, coconut @ Topolobampo, Chicago, IL

55M presented with first episode of paroxysmal atrial fibrillation proven on resting ECG in the GP practice. Echocardiogram showed structurally normal heart. The cardiologist decided to manage conservatively without starting anti-arrhythmics right now. Which of the following risk factor management should be part of his AF treatment and prevention?

Read more
In Drug Treatment, Lifestyle modification, Hypertension, Atrial fibrillation Tags Atrial fibrillation, weight, obesity, alcohol, hypertension

ACC AHA Hypertension Guidelines 2017 – What’s new?

February 1, 2018 Andrew To
@ AHA Meeting in Anaheim 2017 - taking notes

@ AHA Meeting in Anaheim 2017 - taking notes

The ACC/AHA Hypertension Guidelines 2017 was released in the AHA meeting in Anaheim, Californiain November 2017.

While there were a lot of changes, I think it has simplified a lot of the complexities surrounding treatment threshold and goal.

Read more
In Drug Treatment, Hypertension Tags hypertension, calcium channel blocker, ACE inhibitor, beta blocker

“My cholesterol is almost normal – why do I need statins, doctor?”

January 31, 2018 Andrew To
Baja hiramasa yellowtail, pineapple two ways, achiote infused agave @Topolobampo, Chicago, IL

Baja hiramasa yellowtail, pineapple two ways, achiote infused agave @Topolobampo, Chicago, IL

Traditionally, we are taught that laboratory tests have “normal ranges”, such as in haemoglobin or creatinine.  However, this concept of “normal”, when applied in cholesterol measurement, often creates confusion amongst some clinicians and certainly in most patients.

Read more
In Drug Treatment, Hypertension Tags Statins, Risk assessment, hypertension

NSAIDs and MI risk

September 11, 2017 Andrew To
One-man-band on St Kilda Road, Melbourne

One-man-band on St Kilda Road, Melbourne

Nonsteroidal anti-inflammatory drugs (NSAIDs) use is associated with a significantly increased risk for myocardial infarction (MI). This includes naproxen, considered by some as one of the safest drugs in this class. This is according to a new patient level meta-analysis from the University of Montreal, studying celecopxib, diclofenac, ibuoprofen, naproxen and rofecoxib.

Read more
In Drug Treatment, Myocardial infarction Tags Side effects, myocardial infarction, NSAIDs

Patient centered discussion of primary prevention statin therapy

September 5, 2017 Andrew To
Mayo clinic Statin Choice Decision Aid

Mayo clinic Statin Choice Decision Aid

The Mayo clinic has recently published an electronic tool called “Statin Choice Decision Aid”, which is immensely valuable in helping patients visualize cardiovascular risk, and the benefit of statin medications as applied to them.

Read more
In Drug Treatment Tags Statins, myocardial infarction, Side effects, primary prevention

ECG Case 2016-09

September 4, 2016 Andrew To
ECG black and white.001.jpg

32-year-old man presented with cough, breathlessness on exertion and interscapular pain. His ECG was as below.

- Reassure

- CXR, reassure

- CXR, take a more detailed history, then reassure

- CXR, full history, refer for further assessment

Read more
In ECG Case Tags ECG, Syncope, Wolff-Parkinson-White

Individual risk assessment - a common scenario

September 4, 2016 Andrew To
1906 San Francisco Fire Sacramento Street; Photo from Arnold Genthe from the Library of Congress

1906 San Francisco Fire Sacramento Street; Photo from Arnold Genthe from the Library of Congress

A 40-year-old Maori man came for routine review concerned because his 38-year-old brother, who was a smoker, died suddenly of a heart attack. The patient was athletic, previously played professional rugby, without clinical risk factors.

-      BMI 28

-      LDL 4.9; TC/HDL ratio 4

His calculated cardiovascular risk on these parameters was low. A reasonable approach would include

1)     reinforcing healthy living and reassessing in 5 years

2)     reinforcing healthy lifestyle and starting a statin

3)     reinforcing healthy lifestyle, getting a CTCA, starting a statin

4)     all of the above

Read more
In Drug Treatment Tags Statins, coronary artery disease, CT coronary angiography, Risk assessment

Are cardiologists obsessed with statins?

September 4, 2016 Andrew To

Sam is a 60-year-old male heart attack survivor who had an unremarkable recovery after the successful coronary artery stenting in the middle of the night of his presentation. Now it is 3 months and Sam feels absolutely grand. At follow-up, his cardiologist insists that he should continue all the prescribed medications. He read on the internet some bad press about statin medications and thought, “surely, nothing will happen if I stop taking statins?!”

Read more
In Drug Treatment Tags Side effects, Statins, myocardial infarction
← Newer Posts Older Posts →

Copyright @2024 Cardiology Institute; All photos copyright @2024 Andrew To